Physician

Jawad Bilal, M.D

According to 2025 Medicare claims, Jawad Bilal, M.D (NPI: 1174939623) practices rheumatology in the Tucson, AZ market, with the plurality of this provider's patient population coming from Pima, AZ. This provider's primary affiliated billing organization is ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES P C (NPI: 1366489254; TIN: 860765242) and primary practice location at 85748-0002. Bilal is affiliated with the IRCCO (ACO ID: A2619), Banner Network Southern Arizona, LLC (ACO ID: A5178), Sound Physicians Long Term Care Management, LLC (ACO ID: A5220), and ABC Network (ACO ID: A5554), participating under the MSSP model.

Bilal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 353 traditional Medicare patients, billed 78,045 HCPCS/CPT codes, and received $990,831 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,366 prescription claims across 325 beneficiaries totaling $2,285,577 in drug costs, led by Enbrel Sureclick (Etanercept). Open Payments data shows 159 records totaling $7,511. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $2,166 to $990,831. Similarly, Part D prescription costs have moved sharply higher in recent years, from $13,423 to $2,285,577. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	14	14	$2,166
2020	92	149	$11,728
2021	122	240	$19,918
2022	148	245	$19,297
2023	237	26,415	$385,471
2024	353	78,045	$990,831

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	48	126	$13,423
2016	40	166	$13,160
2017	24	105	$6,111
2018	52	154	$93,183
2019	92	382	$383,946
2020	77	464	$819,259
2021	90	556	$1,073,966
2022	99	587	$1,072,612
2023	216	745	$769,664
2024	325	1,366	$2,285,577

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	243	495	$89
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	148	224	$12
80053	Blood test, comprehensive group of blood chemicals	180	323	$10
36415	Insertion of needle into vein for collection of blood sample	232	459	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	157	280	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	64	1,904	$537,524
Humira(Cf) Pen	Adalimumab	54	1,740	$518,200
Privigen	Immun Glob G(Igg)/Pro/Iga 0-50	11	308	$190,061
Orencia Clickject	Abatacept	22	784	$163,022
Cimzia (2 Pack)	Certolizumab Pegol	17	476	$98,835

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	157	$5,471	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$2,040	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jawad Bilal, M.D?

Tedicare shows public-source Medicare data for Jawad Bilal, M.D (NPI 1174939623), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jawad Bilal, M.D have ACO affiliation data?

Jawad Bilal, M.D is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619), Banner Network Southern Arizona, LLC (MSSP, ACO ID A5178), Sound Physicians Long Term Care Management, LLC (MSSP, ACO ID A5220), and ABC Network (MSSP, ACO ID A5554).

What billing organization is linked to Jawad Bilal, M.D?

Jawad Bilal, M.D is linked to ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES P C (billing NPI 1366489254) in the available physician profile data.

Does Jawad Bilal, M.D have Open Payments data?

Jawad Bilal, M.D has 159 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.